Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
Article first published online: 13 FEB 2014
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 105, Issue 3, pages 347–353, March 2014
How to Cite
Cancer Sci 105 (2014) 347–353
- Issue published online: 6 MAR 2014
- Article first published online: 13 FEB 2014
- Accepted manuscript online: 10 JAN 2014 12:36AM EST
- Manuscript Accepted: 28 DEC 2013
- Manuscript Revised: 19 DEC 2013
- Manuscript Received: 15 SEP 2013
- Novartis Pharma. Grant Number: CBKM120X1101
Vol. 105, Issue 4, 498, Article first published online: 11 APR 2014
|cas12350-sup-0001-FigS1.docx||Word document||74K||Fig. S1. Best percentage change from baseline in target lesions according to dose of buparlisib and radiologic response.|
|cas12350-sup-0002-FigS2.docx||Word document||179K||Fig. S2. Mean buparlisib plasma concentration profile on (A) Cycle 1 Day 1; (B) Cycle 1 Day 8; and (C) Cycle 1 Day 28 (pharmacokinetics analysis set).|
|cas12350-sup-0003-TableS1.docx||Word document||20K||Table S1. Criteria for dose-limiting toxicities.|
|cas12350-sup-0004-TableS2.docx||Word document||19K||Table S2. Criteria for grading non-CTCAE adverse events.|
|cas12350-sup-0005-DataS1.docx||Word document||17K||Data S1. Information on pharmacodynamic analyses.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.